Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test (scientific article published on October 26, 2010)

Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins

Q48103651

A method for the routine assessment of fore- and hindlimb grip strength of rats and mice

Q67006702

Inhibition of neuromuscular transmission in isolated mouse phrenic nerve-diaphragm by the enterotoxin of Clostridium perfringens type A

Q67503588

Measurement of botulinum toxin activity: evaluation of the lethality assay

Q72171252

Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A

Q81338936

P433

issue

P407

language of work or name

English

Q1860

P1104

number of pages

P304

page(s)

93-99

P577

publication date

2010-10-26

P1433

published in

Toxicon

Q7830412

P1476

title

Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test

P478

volume

Reverse relations

cites work (P2860)

Q48278483	Azemiopsin, a Selective Peptide Antagonist of Muscle Nicotinic Acetylcholine Receptor: Preclinical Evaluation as a Local Muscle Relaxant
Q58805104	Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q⁻K Peptide Bond Exhibit Unique Catalytic Properties and Substrate Specificities
Q34583087	Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1
Q42862415	Botulinum neurotoxin type A subtype 2 confers greater safety than subtype 1 in a rat Parkinson's disease model
Q37264589	Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro
Q92690319	Crystal structure of botulinum neurotoxin subtype A3 cell binding domain in complex with GD1a co-receptor ganglioside
Q37677078	Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C
Q26778129	Current status and future directions of botulinum neurotoxins for targeting pain processing
Q37090528	Diversity of Group I and II Clostridium botulinum Strains from France Including Recently Identified Subtypes
Q40442566	Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons
Q36315520	In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.
Q57793438	Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6
Q35058841	Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
Q84564091	Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models
Q35532054	Subunit vaccine efficacy against Botulinum neurotoxin subtypes
Q55105284	The Expanding Therapeutic Utility of Botulinum Neurotoxins.
Q53136780	Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.
Q57808978	Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics

P356	DOI	10.1016/J.TOXICON.2010.10.009
P953	full work available at URL	https://api.elsevier.com/content/article/PII:S0041010110003909?httpAccept=text/xml
		https://api.elsevier.com/content/article/PII:S0041010110003909?httpAccept=text/plain
P698	PubMed publication ID	21029745